139183-98-5 Usage
General Description
5,6,7,8-Tetrahydro-imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester is a chemical compound with the molecular formula C10H13N2O2. It is a methyl ester derivative of imidazo[1,2-a]pyridine-6-carboxylic acid and is commonly used in drug development and pharmaceutical research. 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLIC ACID METHYL ESTER has been studied for its potential therapeutic applications, including as a possible treatment for neurological disorders and cancer. It is known for its ability to modulate certain cellular processes and has shown promise in preclinical studies. Additionally, it has the potential to serve as a valuable intermediate in the synthesis of other biologically active compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 139183-98-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,9,1,8 and 3 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 139183-98:
(8*1)+(7*3)+(6*9)+(5*1)+(4*8)+(3*3)+(2*9)+(1*8)=155
155 % 10 = 5
So 139183-98-5 is a valid CAS Registry Number.
139183-98-5Relevant articles and documents
Solid dispersions containing an apoptosis-inducing agent
-
Page/Page column 258-259, (2019/03/15)
A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.